Key result
Stimulating the apelinergic system shows potential to mitigate doxorubicin-induced cardiotoxicity in preclinical models.
Why the study?
Doxorubicin causes long-term cardiovascular complications, and further research is needed to understand the mechanism and therapeutic potential of the apelinergic system to mitigate this damage.
The apelinergic system represents a potential therapeutic target to mitigate doxorubicin-induced cardiotoxicity, warranting further preclinical investigation.
Apelinergic stimulation remains investigational for doxorubicin cardiotoxicity; leaves open need for translational studies before any clinical consideration.
Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Matusik et al. (2024) conducted a review in Doxorubicin-induced cardiotoxicity. Apelinergic system stimulation was evaluated. Stimulating the apelinergic system shows potential therapeutic benefits in protecting the heart and mitigating doxorubicin-induced cardiotoxicity in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: